Mycophenolat Mofetil Sandoz (Mycophenolate Mofetil)

Mycophenolate Mofetil is used in the management of immune‑mediated conditions, particularly in transplant and autoimmune settings.

• Kidney transplantation: helps prevent acute graft rejection.
• Heart transplantation: reduces the risk of early rejection episodes.
• Liver transplantation: supports long‑term graft survival.
• Lupus nephritis: contributes to disease control and renal protection.
• Vasculitis: assists in achieving remission of systemic vascular inflammation.

• Mycophenolate Mofetil is a selective inhibitor of inosine monophosphate dehydrogenase (IMPDH), the key enzyme for de novo guanosine nucleotide synthesis. By limiting guanosine pools, it suppresses proliferation of T‑ and B‑lymphocytes, which rely heavily on this pathway, thereby attenuating the immune response that drives graft rejection and autoimmune activity.

Mycophenolate Mofetil may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Diarrhea: frequent loose stools, often self‑limiting.
• Headache: transient cranial discomfort.
• Tremor: fine shaking of hands or limbs.

Serious or Rare Side Effects

• Bone marrow suppression: leading to anemia, leukopenia or thrombocytopenia.
• Severe infections: opportunistic pathogens such as CMV or fungal species.
• Hepatotoxicity: elevated liver enzymes or hepatitis.
• Progressive multifocal leukoencephalopathy (PML): rare demyelinating brain disease.

Prior to initiating therapy, clinicians should assess baseline laboratory parameters and consider patient‑specific risk factors.

• Monitor blood counts: perform regular CBC to detect marrow suppression.
• Assess liver function: check transaminases and bilirubin periodically.
• Avoid live vaccines: immunosuppression can increase infection risk.
• Use caution in pregnancy: potential fetal risk requires risk‑benefit evaluation.
• Store below 25°C: keep in the original pack, protect from moisture.

Mycophenolate Mofetil interacts with several agents that may alter its efficacy or safety.

Major Interactions (Avoid)

• Azathioprine: additive bone marrow toxicity.
• Cyclosporine or tacrolimus: increased mycophenolate exposure, risk of nephrotoxicity.
• Live vaccines: heightened risk of disseminated infection.

Moderate Interactions (Monitor Closely)

• Antacids containing aluminum or magnesium: may reduce absorption.
• Warfarin: potential alteration of anticoagulant effect.
• NSAIDs: increased risk of gastrointestinal bleeding.